Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain

Completed · Phase 2

Conditions studied: Pain, Cancer, Sickle Cell Anemia, Severe Burns

In brief

The objective of the study is to monitor the safety (adverse event data) of longer-term use of ACTIQ (Oral Transmucosal Fentanyl Citrate \[OTFC\]) treatment in children with pain associated with cancer, sickle cell disease, or severe burns and breakthrough pain (BTP) who are receiving around the clock (ATC) opioid therapy.

Key facts

Study ID
NCT00236093
Run by
Cephalon
Starts
2006-10-01
Last updated by the study team
2014-05-09

Who can join

Age: 3 and older, up to 15. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.